AR084500A1 - Tableta multicapa para tratar la infeccion por hiv en un humano - Google Patents

Tableta multicapa para tratar la infeccion por hiv en un humano

Info

Publication number
AR084500A1
AR084500A1 ARP110104318A ARP110104318A AR084500A1 AR 084500 A1 AR084500 A1 AR 084500A1 AR P110104318 A ARP110104318 A AR P110104318A AR P110104318 A ARP110104318 A AR P110104318A AR 084500 A1 AR084500 A1 AR 084500A1
Authority
AR
Argentina
Prior art keywords
layer
tablet
human
hiv infection
treat hiv
Prior art date
Application number
ARP110104318A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084500(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR084500A1 publication Critical patent/AR084500A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Tabletas multicapas que contienen rilpivirina clorhidrato, emtricitabina y tenofivir disoproxil fumarato. Las tabletas son útiles para el tratamiento del HIV.Reivindicación 1: Una tableta que comprende una primera capa y una segunda capa donde: a) la primera capa comprende rilpivirina HCI y está sustancialmente libre de tenofovir disoproxil fumarato; b) la segunda capa comprende tenofovir disoproxil fumarato y está sustancialmente libre de rilpivirina HCI; y c) la tableta comprende además emtricitabina. Reivindicación 18: La tableta de acuerdo con cualquiera de las reivindicaciones 1 - 16 que además comprende una tercera capa que está interpuesta y que separa la primera capa de la segunda capa. Reivindicación 19: La tableta de acuerdo con la reivindicación 18 en la cual la tercera capa comprende lactosa monohidrato y/o celulosa microcristalina.
ARP110104318A 2010-11-19 2011-11-18 Tableta multicapa para tratar la infeccion por hiv en un humano AR084500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
AR084500A1 true AR084500A1 (es) 2013-05-22

Family

ID=45094284

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104318A AR084500A1 (es) 2010-11-19 2011-11-18 Tableta multicapa para tratar la infeccion por hiv en un humano
ARP200103214A AR123409A2 (es) 2010-11-19 2020-11-19 Composiciones terapéuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200103214A AR123409A2 (es) 2010-11-19 2020-11-19 Composiciones terapéuticas

Country Status (35)

Country Link
US (1) US10857102B2 (es)
EP (2) EP2826466A1 (es)
JP (2) JP2014500261A (es)
KR (1) KR101923103B1 (es)
CN (2) CN106511357A (es)
AP (1) AP3816A (es)
AR (2) AR084500A1 (es)
AU (3) AU2011329642B2 (es)
BR (1) BR112013012245B1 (es)
CA (1) CA2818097C (es)
CL (1) CL2013001402A1 (es)
CO (1) CO6761300A2 (es)
CR (1) CR20130293A (es)
DK (1) DK2640362T4 (es)
EA (2) EA025852B1 (es)
EC (2) ECSP13012700A (es)
ES (1) ES2524408T5 (es)
HK (2) HK1206592A1 (es)
HR (1) HRP20140946T1 (es)
IL (1) IL226300B (es)
MA (1) MA34735B1 (es)
ME (1) ME01980B (es)
MX (1) MX347512B (es)
MY (1) MY185604A (es)
NZ (1) NZ610729A (es)
PE (3) PE20140163A1 (es)
PL (1) PL2640362T5 (es)
PT (1) PT2640362E (es)
RS (1) RS53691B1 (es)
SG (3) SG10201509521WA (es)
SM (1) SMT201400150B (es)
TW (1) TWI556840B (es)
UA (1) UA114075C2 (es)
WO (1) WO2012068535A1 (es)
ZA (1) ZA201304481B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224916A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
MX347512B (es) 2010-11-19 2017-04-28 Gilead Sciences Inc Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir.
PE20141328A1 (es) 2011-08-16 2014-10-04 Gilead Sciences Inc Tenofovir alafenamida hemifumarato
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
PT3608325T (pt) 2012-12-21 2022-10-17 Gilead Sciences Inc Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PL3346995T3 (pl) 2015-11-09 2020-03-31 Gilead Sciences, Inc. Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
WO2019003150A2 (en) 2017-06-30 2019-01-03 Viiv Healthcare Company ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
US20210000823A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1448170A4 (en) 2001-11-27 2010-05-12 Bristol Myers Squibb Co EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
US20040224916A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
ES2371442T7 (es) 2004-09-02 2022-05-12 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2625776A1 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
AU2006325404B2 (en) 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
PL2487161T3 (pl) * 2007-02-23 2017-03-31 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
AU2008253803A1 (en) 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
HUE025822T2 (en) 2009-02-06 2016-04-28 Gilead Sciences Inc Dual layer tablets containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir
LT2480552T (lt) 2009-09-21 2017-02-10 Gilead Sciences, Inc. 2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymui
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
MX347512B (es) 2010-11-19 2017-04-28 Gilead Sciences Inc Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir.

Also Published As

Publication number Publication date
KR101923103B1 (ko) 2018-11-28
CO6761300A2 (es) 2013-09-30
US20130243857A1 (en) 2013-09-19
PT2640362E (pt) 2014-11-28
PE20140163A1 (es) 2014-02-08
ZA201304481B (en) 2022-03-30
CN103491948B (zh) 2016-11-02
WO2012068535A1 (en) 2012-05-24
AR123409A2 (es) 2022-11-30
JP6138851B2 (ja) 2017-05-31
ME01980B (me) 2015-05-20
CA2818097A1 (en) 2012-05-24
BR112013012245A2 (pt) 2016-08-09
ES2524408T3 (es) 2014-12-09
CN103491948A (zh) 2014-01-01
UA114075C2 (xx) 2017-04-25
AU2018202635A1 (en) 2018-05-10
IL226300B (en) 2019-05-30
AU2011329642A1 (en) 2013-05-02
NZ610729A (en) 2015-10-30
DK2640362T3 (en) 2014-12-01
TW201238612A (en) 2012-10-01
EA025852B1 (ru) 2017-02-28
AU2016208417B2 (en) 2018-04-05
BR112013012245B1 (pt) 2022-09-27
HK1206592A1 (en) 2016-01-15
JP2014500261A (ja) 2014-01-09
PE20211657A1 (es) 2021-08-24
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
CL2013001402A1 (es) 2013-12-27
PL2640362T3 (pl) 2015-03-31
MY185604A (en) 2021-05-25
CR20130293A (es) 2013-10-03
PE20170521A1 (es) 2017-05-27
US10857102B2 (en) 2020-12-08
HRP20140946T1 (hr) 2015-02-13
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
MX2013005669A (es) 2013-11-04
SG10201509521WA (en) 2015-12-30
EP2640362B1 (en) 2014-09-10
SMT201400150B (it) 2015-01-15
EA201691695A1 (ru) 2017-11-30
CA2818097C (en) 2019-07-30
MA34735B1 (fr) 2013-12-03
AP2013006931A0 (en) 2013-06-30
JP2015131853A (ja) 2015-07-23
EP2826466A1 (en) 2015-01-21
PL2640362T5 (pl) 2022-05-02
RS53691B1 (en) 2015-04-30
KR20140037799A (ko) 2014-03-27
AP3816A (en) 2016-09-30
EP2640362A1 (en) 2013-09-25
AU2016208417A1 (en) 2016-08-18
EA201390651A1 (ru) 2013-11-29
SG10201912527XA (en) 2020-02-27
ES2524408T5 (es) 2022-04-25
SG190333A1 (en) 2013-06-28
TWI556840B (zh) 2016-11-11
ECSP13012700A (es) 2013-08-30
HK1190064A1 (en) 2014-06-27
MX347512B (es) 2017-04-28
EP2640362B2 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
AR123409A2 (es) Composiciones terapéuticas
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
USD763454S1 (en) Toe separator
CR20190073A (es) FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
MX350875B (es) Formas de dosificacion farmaceutica de liberacion controlada.
EA201291158A1 (ru) Комбинированные вакцины с синтетическими наноносителями
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
PE20110119A1 (es) Asociacion entre ferroquina y artesunato para el tratamiento del paludismo
CL2011001885A1 (es) Tableta bicapa oral en donde la primera capa comprende al compuesto de formula i (elvitegravir) y al compuesto de formula ii, y la segunda capa comprende al compuesto de formula iii (emtricitabina) y a la sal de formula iv (sal de tenofovir); metodo para la preparacion, util en el tratar infecciones por vih.
NZ738524A (en) Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
MX2021002321A (es) Nuevos metodos.
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
IN2013CH05288A (es)
PE20151282A1 (es) Combinacion de medicamentos que comprenden fenilefrina y paracetamol
AR125919A2 (es) Formas de dosificación de ruxolitinib de liberación sostenida
MX2011005899A (es) Composicion farmacéutica con antihistamínico no sedante y combinaciones.
TH171908A (th) องค์ประกอบบำบัดที่ประกอบรวมด้วย ริลพิวิรีน HCL (rilpivirine HCL) และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate)
AR106645A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
MX355000B (es) Composición farmacéutica en microesferas con antihistamínico no sedante y antiemético.
ECSP15025357A (es) Formas de dosificación de ruxolitinib de liberación sostenida
AR100910A1 (es) Forma de dosificación oral de liberación sostenida que contiene morfina y naloxona
MX2010006317A (es) Composicion farmaceutica oral con antihistaminico y descongestionante.
AR098884A1 (es) Alteraciones de activación de notch en el cáncer de mama
CN302359656S (zh) 包装盒（补血调经片）

Legal Events

Date Code Title Description
FC Refusal